Entity

Time filter

Source Type

Pentéli, Greece

De Gucht V.,Leiden University | Papavasiliou A.,Pendeli Childrens Hospital | Maes S.,Leiden University
Epilepsy and Behavior | Year: 2015

The aim of this cross-sectional study was to explore the extent to which gender, epilepsy severity, and self-regulation concepts (illness perceptions, autonomous treatment regulation, perceived autonomy support by parents) predict psychological distress and quality of life (QoL) in young patients with epilepsy. Structured interviews were conducted in 100 patients (. Mage=. 13.9, SD=. 2.21, 41% girls), and data were analyzed by means of multiple hierarchical regression analyses. Seizures of most patients (91%) were well controlled by antiepileptics, 3% of the patients had infrequent seizures, and seizures in 6% were pharmacoresistant. At a multivariate level, it appeared that youngsters with epilepsy who expect that their disease will last for a long time, who believe that they have less personal control over their illness, and who expect the illness to have a high emotional impact reported higher levels of distress. In addition, a better QoL was reported by youngsters who believed that treatment did not control their illness and who thought that their epilepsy would not affect them emotionally. Findings indicate the importance of illness perceptions, and it is suggested that they should be targeted in future interventions in youngsters with epilepsy. © 2015 Elsevier Inc.. Source


Rizou I.,AGELON ? | Rizou I.,AGELON ? | De Gucht V.,Leiden University | Papavasiliou A.,Pendeli Childrens Hospital | Maes S.,Leiden University
European Journal of Paediatric Neurology | Year: 2016

Purpose The present study aims to explore the extent to which gender, epilepsy severity and illness perceptions predict fatigue and sleep problems in youngsters with epilepsy. Method Structured interviews were conducted in 100 young patients (Mage = 13,9, SD = 2.21; 41% girls) and data were analyzed by means of multiple hierarchical regression analyses. Results Most patients (91%) were well controlled by anti-epileptics; 3% had infrequent seizures and 6% were pharmacoresistant. At a multivariate level it appeared that youngsters with epilepsy who believe that they have less personal control over their illness and who feel that the illness has a high emotional impact on their lives reported higher levels of fatigue. In addition, more sleep problems were reported by youngsters who think they have less personal control over the disease, who believe that treatment controls epilepsy and report that the disease has a high emotional impact on their lives. Conclusion Given the importance of illness perceptions, it is suggested that they are targets for future interventions that aim to reduce fatigue and sleep problems in youngsters with epilepsy. © 2015 European Paediatric Neurology Society. Source


Heinen F.,Ludwig Maximilians University of Munich | Desloovere K.,University Hospital of Pellenberg | Schroeder A.S.,Ludwig Maximilians University of Munich | Berweck S.,Specialist Center for Paediatric Neurology | And 33 more authors.
European Journal of Paediatric Neurology | Year: 2010

An interdisciplinary European group of clinical experts in the field of movement disorders and experienced Botulinum toxin users has updated the consensus for the use of Botulinum toxin in the treatment of children with cerebral palsy (CP). A problem-orientated approach was used focussing on both published and practice-based evidence. In part I of the consensus the authors have tabulated the supporting evidence to produce a concise but comprehensive information base, pooling data and experience from 36 institutions in 9 European countries which involves more than 10,000 patients and over 45,000 treatment sessions during a period of more than 280 treatment years. In part II of the consensus the Gross Motor Function Measure (GMFM) and Gross Motor Function Classification System (GMFCS) based Motor Development Curves have been expanded to provide a graphical framework on how to treat the motor disorders in children with CP. This graph is named "CPGraph Treatment Modalities - Gross Motor Function" and is intended to facilitate communication between parents, therapists and medical doctors concerning (1) achievable motor function, (2) realistic goal-setting and (3) treatment perspectives for children with CP. The updated European consensus 2009 summarises the current understanding regarding an integrated, multidisciplinary treatment approach using Botulinum toxin for the treatment of children with CP. © 2009 European Paediatric Neurology Society. Source


Maria V.,Mitera Maternity and Childrens Hospital | Elias K.,Pendeli Childrens Hospital | Konstantinos F.,Pendeli Childrens Hospital
Journal of Pediatric Orthopaedics Part B | Year: 2011

Haemolymphangiomas are congenital malformations of the vascular system, benign in origin. They can be either defined at birth or in early childhood, but the recurrence rate is usually high and complete resection is difficult to be achieved. We report two cases of haemolymphangiomas present at the tibias. We used radiographic control, ultrasound and magnetic resonance to detect the nature of the tumour and the anatomical relation with the surrounding tissues providing the appropriate surgical treatment. The diagnosis was confirmed postoperatively by histopathology. The first case presented multiple recurrences because of insufficient draining and immobilization of the leg, whereas the second case had no complications or recurrence postoperatively. Both patients had no complications or recurrence in 24-month follow-up. Haemolymphangiomas are very challenging to be treated as they can grow slowly and remain asymptomatic for many years. Sometimes they can be very aggressive in growth without characteristics of malignancy. The choice of treatment is the complete surgical excision of the tumour, sufficient and long-lasting draining, and immobilization of the extremity to abolish the possibility of recurrence. Other methods of treatment did not show better results than surgical resection. Copyright © 2011 Lippincott Williams & Wilkins. Source


Gavatha M.,Pendeli Childrens Hospital | Ioannou I.,Pendeli Childrens Hospital | Papavasiliou A.S.,Pendeli Childrens Hospital
Epilepsy and Behavior | Year: 2011

The results of adjunctive lacosamide treatment in 18 pediatric patients with pharmacoresistant focal epilepsy are reported. All had severe forms of focal epilepsy with or without secondary generalization and were concurrently receiving one to three other antiepileptic drugs. Lacosamide was administered orally, and final dose, after slow titration, ranged between 1.7 and 10. mg/kg. Mean treatment duration was 8. months (range = 3. weeks-17. months). Treatment efficacy was assessed at two time points with a 1-year interval. The reported greater than 50% reduction in seizure frequency was 36% in the initial short-term and 20% in the following long-term assessment. Side effects, mostly somnolence and irritability, were reported by 39% of patients in both evaluations. Our data suggest that lacosamide treatment in pediatric patients is safe at doses up to 10. mg/kg/day without any major side effects, but studies in larger series are needed to validate and extend these findings. © 2011 Elsevier Inc. Source

Discover hidden collaborations